Chromosomal Microarray Analysis (CMA) for Hematological Malignancies

UW Cytogenetic Services and Molecular Genetics is now offering a chromosomal microarray analysis (CMA) for hematological malignancies

CMA analysis provides a high resolution, genome-wide assessment of copy number variants (gains and losses) and copy neutral loss of heterozygosity (cn-LOH) recurrent in hematological malignancies.

CMA is recommended for individuals with a new diagnosis or suspected diagnosis of a hematological disease, or individuals with relapsed disease. The results are intended for use by the physician to further refine diagnoses, offer more accurate prognostic assessments and select optimal treatments.

CMA can reveal additional genomic imbalances not detectable by chromosomes or FISH and increase the diagnostic yield for a clonal marker from 50% to approximately 80% in myeloid malignancies.

Contact UW Cytogenetic Services and Molecular Genetics at 608-262-0402 for more information.

Information for Medical Providers